Immunovant, Inc.

NasdaqGS IMVT

Immunovant, Inc. Market Capitalization on January 14, 2025: USD 3.36 B

Immunovant, Inc. Market Capitalization is USD 3.36 B on January 14, 2025, a -45.14% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Immunovant, Inc. 52-week high Market Capitalization is USD 6.12 B on January 16, 2024, which is 82.27% above the current Market Capitalization.
Immunovant, Inc. 52-week low Market Capitalization is USD 3.34 B on January 13, 2025, which is -0.57% below the current Market Capitalization.
Immunovant, Inc. average Market Capitalization for the last 52 weeks is USD 4.38 B.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqGS: IMVT

Immunovant, Inc.

CEO	Dr. Peter Salzmann M.B.A., M.D.
IPO Date	June 21, 2019
Location	United States
Headquarters	320 West 37th Street
Employees	207
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Key trends

Past 5 years